Isavuconazol no tratamento da Aspergilose e da Mucormicose no Sistema de Saúde Privado Brasileiro

Marcos Santos; Jaime Rocha; Emerson Gatti; Bruno Marques; Lívia Maria Gonçalves Barbosa; Rodrigo Dodt

doi:10.66305/jbas.v5i2.28

Isavuconazole for the Treatment of Aspergillosis and Mucormycosis in the Brazilian Private Healthcare System

Authors

Marcos Santos Sociedade Brasileira de Auditoria Médica, Presidente
Jaime Rocha Médico clínico e infectologista. Professor de medicina da PUC-PR
Emerson Gatti Onco-Hematologista. Médico responsável Técnico pelo serviço verticalizado de Onco Hematologia da Unimed de Campinas
Bruno Marques Knigth Therapeutics Brasil
Lívia Maria Gonçalves Barbosa Knigth Therapeutics Brasil
Rodrigo Dodt Knigth Therapeutics Brasil

DOI:

https://doi.org/10.66305/jbas.v5i2.28

Keywords:

Isavuconazole, Mucormycosis, Aspergillosis

Abstract

The text analyzes the use of isavuconazole in the treatment of invasive fungal infections within the Brazilian private healthcare system. It begins by highlighting that these infections are associated with high mortality among immunocompromised patients and that the choice of antifungal therapy should consider efficacy, safety, drug interactions, pharmacokinetics, and the availability of both intravenous and oral formulations.

Downloads

PDF (Português (Brasil))

Published

2026-02-06

How to Cite

Santos, M., Rocha, J., Gatti, E., Marques, B., Maria Gonçalves Barbosa, L., & Dodt, R. (2026). Isavuconazole for the Treatment of Aspergillosis and Mucormycosis in the Brazilian Private Healthcare System. Brazilian Journal of Health Auditing, 5(2), 9–24. https://doi.org/10.66305/jbas.v5i2.28